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APREPITANT (AP) FOR PREVENTION OF NAUSEA AND VOMITING SEC-
ONDARY TO HIGH-DOSE CYCLOPHOSPHAMIDE (CY) ADMINISTERED
TO PATIENTS UNDERGOING AUTOLOGOUS (A) PERIPHERAL BLOOD
PROGENITOR CELL (PBPC) MOBILIZATION: FINAL RESULTS OF A PHASE
II TRIAL
Abidi, M.H.1,2, Ratanatharathorn, V.1,2, Abrams, J.1,2, Ibrahim, R.3,
Cronin, S.3, Al-Kadhimi, Z.1,2, Lum, L.1,2, Ventimiglia, M.2,
Ayash, L.1,2, Uberti, J.1,2 1Wayne State University, Detroit, MI; 2Bar-
bara Ann Karmanos Cancer Center, Detroit, MI; 3Eugene Appelbaum
College of Pharmacy and Allied Health Professions, Detroit, MI
AP is a neurokinin-1 receptor antagonist with unique anti-
emetic activity. We conducted a phase II trial evaluating efficacy
& safety of AP in combination with 5-HT3 antagonists & ad-
justed dose of dexamethasone (D) in pts receiving high-dose
CY for stem cell mobilization. High-dose CY is associated with
significant nausea & vomiting. CY and filgrastim provides a better
PBPC yield as compared to filgrastim (failure rate15-20%). Pri-
mary endpoint was the control of vomiting without the use of
rescue anti-emetics at 24 hours after high dose CY. Secondary
objectives were to evaluate side effects, control of nausea & de-
layed vomiting. Tertiary objective was to estimate the rate of suc-
cessful CD34+ mobilization (minimum 2 million CD 34+ cells/kg
body weight).
Methods: From May 2005 to June 2009, 40 pts were enrolled,
five of whom were not evaluable for response. All received CY
4gm/m2 and filgrastim (10-16mcg/kg/d). Granisetron 1 mg, (D)
10 mg and AP 125 mg were given orally 1 hour before CY fol-
lowed by AP 80 mg once daily  2 days. We used Simons opti-
mal two-stage design constrained to fewer than 40 pts with 10%
type I error and 85% statistical power. AP is judged to be of suf-
ficient efficacy for further evaluation if it prevents acute vomiting
in. 45% of pts. Under these assumptions, 18 evaluable pts were
enrolled in 1st stage. Acute emesis was controlled in 10 pts
therefore meeting the goal & enrollment proceeded to stage 2.
An additional 17 pts were enrolled in Stage 2. If acute vomiting
is controlled in 20 or more of the 35 pts, AP is judged worthy of
further study.
Results: Twenty out of 35 response-evaluable patients (57%) did
not develop vomiting or require rescue anti-emetics, thus achiev-
ing the critical value for success. A total of 22 (63%) of 35 re-
sponse-evaluable pts met the criterion for the secondaryTable 1. Patients Characteristics
Sex: Male/ Female 20/15
Median Age(years) 48 (range: 23-64)
Race
Caucasians 30
African Americans 4
Native American 1
Diagnosis
APL 1
HD 4
NHL 11
MM 19
Median CD341Cells/kg 7.62 million cells
(range: 1.7 -76.15)
APL: Acute Promyelocytic Leukemia, HD: Hodgkin Disease, MM: Multi-
ple Myeloma, NHL: Non- Hodgkin Lymphomaendpoint of control of delayed vomiting defined as no vomiting
episodes during days 2 – 5 and no rescue medications; exceeding
the critical value for success. Thirty four out of 35 pts had a suc-
cessful stem cell mobilization, thuse far exceeding the critical
value of 23 of 35 pts. Two pts had grade 3 toxicity; 1 had pain
(probably AP related) & another reported diarrhea (possibly AP
related). Thus the rate of serious toxicity was 6% meeting the cri-
terion for acceptable toxicity.
Conclusion:This final analysis demonstrate that AP has potential to
effectively control acute & delayed emesis in pts receiving high-dose
Cy and should be evaluated further.110
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Introduction:Many patients (pts) who are eligible for ASCT are
unable to collect a minimum number of CD34 + stem cells to
support high dose chemotherapy and ASCT. Plerixafor,
a CXCR4 antagonist, in combination with G-CSF mobilizes
more CD34+ stem cells when compared to G-CSF alone. Due
to its cost, we commenced a risk adapted approach to the utili-
zation of plerixafor for stem cell mobilization in pts undergoing
ASCT. Our goal was to add plerixafor in pts who had ineffective
mobilization thereby preventing mobilization failures. Re-mobili-
zation results in added costs, delays with possible disease pro-
gression and time lost for the pts.
Methods: The study was restricted to pts mobilized with 10
mcg/kg/day GCSF alone. There were two patient populations:
those who had plerixafor added in the evening of day 5 if PB
CD 34\10/L with apheresis commencing the following morn-
ing; and those who during apheresis had a daily collection yield
of\0.5  106 CD34/kg. Morning administration of G-CSF and
evening dosing of plerixafor continued daily until apheresis was
complete.
Results: From February to July 2009, 147 mobilization attempts
occurred with G-CSF alone (Myeloma 61, NHL 54, Amyloid 17,
Hodgkin 10, POEMS 4 and 1 solid tumor). Median CD34 yield:
5.5  106 CD34/kg; median apheresis 3. 67 pts (46%) received
plerixafor; 37 during mobilization and 30 during collections.
Overall, 7 of 147 (5%) failed to achieve a minimum of 2 
106 CD34/kg compared to a prior 22% failure rate. Day 4 PB
CD34 count and day 1 apheresis yield were analyzed to predict
who would require plerixafor under these guidelines (Table 1).
72% of pts whose PB CD34\10 on day 4 received plerixafor
vs 10% if $10. 110 pts did not start plerixafor prior to day 1
collection; if day 1 apheresis yield was \1.5, 76% subsequently
received plerixafor.
Conclusions: Implementing this risk adapted approach allows
poor mobilizers to be identified promptly and for initiation of
plerixafor during mobilization and collection, thereby reducing
the number of failures. In pts whose PB CD34\10 on day 4
of G-CSF or whose day 1 yield is \1.5 x106 CD34/kg, earlier
addition of plerixafor may result in fewer apheresis days. Based
on this data, we are implementing the earlier addition of plerix-
afor. This risk adapted approach with early implementation of
plerixafor may be more cost effective than waiting for failureS197
S198 Poster Session Ito mobilize or utilizing combination G-CSF and plerixafor for all
pts as upfront mobilization.
Mobilization and Collection
All Patients Plerixafor No PlerixaforPB CD34 day 4
\10 65 47 (72%) 18 (28%)
10-14 11 4 (36%) 7 (64%)
$15 58 3 (5%) 55 (95%)not done* 12 12 0
Day 1 Apheresis yield
(x10[6] CD34/kg)
\1 15 14 (93%) 1 (7%)
\1.5 33 25 (76%) 8 (24%)
$1.5 77 5 (6%) 72 (94%)*12 patients received Plerixafor on the evening of day 4 due to prior
failure to mobilize or high risk of failure111
THE IMPACT OF PRIOR EXPOSURE TO RITUXIMAB ON AUTOLOGOUS
STEM CELL TRANSPLANTATION IN PATIENTS WITH FOLLICULAR AND
TRANSFORMED LYMPHOMA
Muccilli, A.D., Doucette, S., McDiarmid, S., Huebsch, L.B., Sabloff, M.
The Ottawa Hospital, Ottawa, ON, Canada
Introduction: Addition of rituximab to chemotherapy (CT) for
follicular lymphoma (FL) has been shown to improve many outcome
parameters. Often, high-dose therapy is followed by autologous
stem-cell transplantation (ASCT) after 1, 2 or more relapses. Kang
et al. (BMT (2007) 40, 973) investigated whether prior exposure to
rituximab had any influence on a subsequent ASCT and found no
differences in the outcomes analyzed. However, there has been evi-
dence suggesting that that such prior exposure may alter the pheno-
type of these tumour cells so that they no longer express CD20, and
thus potentially altering their behaviour.
Methods:We performed a retrospective review on all patients hav-
ing received an ASCT at the Ottawa Hospital with an initial diagno-
sis of FL. They were grouped into four categories according to their
prior exposure to or lack of prior exposure to rituximab and accord-
ing to their pre-ASCT diagnosis, non-transformed FL (FL-NT) vs.
transformed (FL-T).
Results: 259 patients who underwent an autoHSCT for FL were di-
vided into 4 groups: 184 FL non-transformed (FL-NT) (31 patients
received rituximab and 153 did not), and 75 FL-transformed (FL-T)
(24 patients received rituximab and 51 did not). The 5-year progres-
sion-free survivals (PFS) were 61.2% and 27.6%, respectively
(p\0.0001) and the overall survivals (OS) were 72.5% and 39.3%,
respectively, (p\0.0001). In the FL-NT group, no differences ex-
isted in PFS or OS between FL-NT rituximab-naı¨ve and rituxi-
mab-treated patients (5-year PFS 61% vs. 64%, p5 0.69; 5-year
OS 73% vs. 68%, p5 0.80).Within the FL-T group, the subsequent
5-year PFS of the rituximab-naive vs. pre-treated groups were 22%
and 55% (p 50.20), respectively, and the 5-year OS were 36% and
51% (p5 0.39), respectively. Prior exposure to R had a positive ef-
fect (Hazard Ratio (HR): 0.44, 95% CI 0.20-0.97, p5 0.04) on
PFS and OS (HR: 0.5, 95% CI 0.21-1.18, p5 0.11).
Conclusion: Pre-treatment with rituximab in FL-NT prior to
ASCTdoes not adversely impact ASCToutcomes.There is a sugges-
tion of an increase in the number of patients with FL-T being trans-
planted in the post-rituximab era and as expected, the FL-T had
a poorer outcome than the FL-NT patients. However, prior expo-
sure to rituximab appeared to demonstrate a trend toward an im-
proved OS within the FL-T group. In summary, previous
rituximab exposuremay be associated with an increased rate of trans-
formation, leading to the poorer outcome of patients originally diag-
nosed with FL-NT.112
CD34 + ALDH+ PERIPHERAL BLOOD STEM CELLS IN CRYOPRESERVED
APHERESIS PRODUCT ARE NON-APOPTOTIC AND PREDICT EARLY AND
LATE ENGRAFTMENT FOLLOWING AUTOLOGOUS TRANSPLANTATION
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Methods which permit discrimination between viable and apopto-
tic peripheral blood stem cells (PBSC) following cryopreservation
may be important in assessing the quality and engraftment potential
of thawed apheresis product used in autologous transplantation. Pre-
vious studies have shown that cryopreservation results in significant
apoptosis in CD34+ cells and that estimation of PBSC number based
on the expression of the functional stem cell marker, aldehyde dehy-
drogenase (ALDH)may provide a better estimate of engraftment po-
tential in cryopreserved product than CD34 alone. We assessed
whether PBSC subset assessment based upon DilC1, a sensitive
marker of mitochondrial membrane potential and apoptosis, to-
gether with the viability exclusion dye 7-AAD, ALDH activity and
CD34 expression may identify subsets which correlate with short
and long term engraftment parameters following cryopreservation
of PBSC apheresis product and autologous transplantation. 35 pts
(median age 596 9yrs) underwent PBSC collection, high dose che-
motherapy and autologous transplantation for haematological ma-
lignancy. Most pts had multiple myeloma (42%) or NHL (40%).
Post thaw mean infused CD34  106/kg was 4.10 (0.05-10.5) and
ALDH  106/kg 2.28 (0.25-6.5). CD34 viability was 72.3% (11.7-
96.0). Most ALDH+ cells were non-apoptotic as assessed by DilC1
staining, 89.9% (55.6-100.0) vs CD34, 34.5% (3.2-84.7),
(p\0.005), and most ALDH+ cells expressed CD34 (71.3%, 33.9-
97.2). Only the CD34 + ALDH+ subset correlated with time to
ANC. 0.5  109/L, (p5 0.049), though a trend was noted for
CD34 +DilC1+ (p5 0.07). No analysed subset could be significantly
correlated to short term platelet recovery (Pl. 20  10/9L). Long
term (day 100) erythroid (Hb .100 g/L) and platelet engraftment
(Pl. 100  109/L) was strongly correlated to numbers of
CD34 +DilC1+ (p\0.005), CD34 + ALDH+ (p\0.005), and
CD34 + ALDH+DilC1+ (p\0.005) in infused product. Assess-
ments of engraftment potential of cryopreserved PBSC’s based on vi-
able CD34 counts may be uninformative unless markers of apoptotic
activity are included for analysis. In contrast, assessments based on
ALDH activity appear to identify a viable and non-apoptotic stem
cell subset correlated to both short term neutrophil and long term
erythroid and platelet engraftment potential following autologous
transplantation. Markers of apoptosis may be redundant when as-
sessing ALDH activity in autologous PBSC product.113
TRANSPLANT UTILIZATION, PROCEDURE PATTERNS AND PATIENT
CHARACTERISTICS IN NORTH AMERICAN TRANSPLANT CENTERS FROM
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Autologous (Auto) and allogeneic (Allo) hematopoietic cell
transplantation (HCT) have been used to cure malignant and
non-malignant conditions for .40 years. Recent advances in
HCT techniques and supportive care, new HCT indications,
and improvements in survival outcomes may have increased access
to and utilization of HCT. We describe the HCT population, uti-
lization and procedure patterns in North American (US and Can-
ada) HCT centers reporting to the CIBMTR from 1994-2005.
We divided the population into six 2-year cohorts (Table). All
data exclude donor lymphocyte infusions. The number of Au-
toHCTs increased by .30% from the mid to late 1990s, then
